People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Chronic low back pain can disrupt your daily life, keeping you from enjoying family moments, outdoor adventures or even simple tasks like walking or sitting comfortably. If traditional treatments ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...